Aclimostat (ZGN-1061) is a highly potent inhibitor of the MetAP2 enzyme that demonstrates promising efficacy and safety profiles in preclinical trials. In a mouse model of obesity and insulin resistance, ZGN-1061 exhibits comparable weight loss efficacy to beloranib, while also improving metabolic parameters. Additionally, ZGN-1061 induces consistent changes in gene transcription in HepG2 cells, further supporting its positive pharmacological effects.